Treace Medical Concepts Appoints New Directors
October 04 2021 - 8:00AM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a commercial-stage orthopaedic medical device
company driving a paradigm shift in the surgical treatment of
Hallux Valgus (commonly known as bunions), today announced the
appointment of Betsy Hanna and Deepti Jain to its Board of
Directors effective October 1, 2021.
“With decades of combined experience in
healthcare leadership, Ms. Hanna and Ms. Jain strengthen the
expertise of our Company’s Board of Directors,” said James T.
Treace, the Company’s Chairman of the Board. “Our executive
leadership and board are pleased to add two individuals with their
stellar reputations, and both will undoubtedly help guide us
through our next phase of growth, as we continue to strive to drive
a paradigm shift in the surgical treatment of bunions and unique
related devices for midfoot correction, such as the recently
introduced Adductoplasty™ Midfoot Correction System.”
Betsy Hanna said, “It is a pleasure to
collaborate with the Board and management of Treace, as we propel
the Company forward, driving growth and increased market
penetration of the Lapiplasty® system, designed to address the root
cause of the bunion. The Company’s recent introduction of its
Adductoplasty™ Midfoot Correction System confirms they are actively
developing and bringing to market relevant pipeline
technologies.”
Ms. Hanna is a global healthcare and biotech
executive who has held leadership roles with Fortune 100 companies,
as well as start-ups. She has led teams through all stages of the
sales process, from product development and launch through
significantly increasing sales and market share. Ms. Hanna
currently serves as President and Chief Executive Officer and a
board member of Clinical Genomics, Inc., a provider of cancer
diagnostic solutions. From 2014 to 2018, Ms. Hanna served as
President and Chief Operating Officer of Origin, Inc., a
clinical-stage biotech company. Ms. Hanna also held positions of
increasing responsibility at Johnson & Johnson, including as
Vice President of Strategic Marketing and a member of the Global
Management Board for J&J Vision Care, where she was responsible
for global agency selection and advertising strategy for J&J's
largest global consumer brand, Acuvue® contact lenses. Ms. Hanna
has a B.S. in Chemical Engineering from the University of Illinois
and an M.B.A. from Harvard Business School.
Deepti Jain added, “Treace is uniquely
positioned in the surgical bunion market, with increasing surgeon
advocacy and clinical data that support the Lapiplasty®
procedure. I am gratified to lend my expertise to the Board
and management of Treace, as we continue to navigate the industry,
building relationships with facilities and providers.”
Ms. Jain has served as a senior executive across
a diverse healthcare landscape including pharmacy benefit
management (PBM), health plans and hospitals. From 2018 to 2020,
Ms. Jain served as President of IngenioRX, the pharmacy benefit
management division of Anthem, Inc. (NYSE: ANTM), a publicly-traded
health benefits company. Ms. Jain also served as Chief Operating
Officer of Pharmacy Solutions for Anthem. Prior to that, Ms. Jain
held positions of increasing responsibility, including Senior Vice
President & Chief Financial Officer of the Health Plan
Division, with Medco Health Solutions, Inc., a publicly traded
pharmacy benefits management company. Ms. Jain currently serves on
the Board of Directors of Tactile Systems Technology, Inc.
(NASDAQ: TCMD), a medical device corporation. Ms. Jain has a B.A.
in Philosophy & Music from Dayanand Anglo Vedic College, India,
an M.A. in English Literature from Guru Nanak Dev University,
India, and an M.B.A., Finance & Investments from Baruch
College, NYC.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a
commercial-stage orthopaedic medical device company with the goal
of advancing the standard of care for the surgical management of
bunion deformities and related midfoot correction. Bunions are
complex 3-dimensional deformities that originate from an unstable
joint in the middle of the foot. Treace has pioneered and patented
the Lapiplasty® 3D Bunion Correction™ system - a combination of
instruments, implants, and surgical methods designed to correct all
3 planes of the bunion deformity and secure the unstable joint,
addressing the root cause of the bunion and helping patients get
back to their active lifestyles. Treace recently expanded its
offering with the Adductoplasty™ Midfoot Correction System,
designed for reproducible correction of the midfoot which could
provide further support to hallux valgus patients. For more
information, please visit www.treace.com.
Contacts:Treace Medical
ConceptsMark L. HairChief Financial
Officermhair@treace.net(904) 373-5940
Investors:Gilmartin GroupLynn
Lewis or Vivian CervantesIR@treace.net
Anthem (NYSE:ANTM)
Historical Stock Chart
From May 2024 to Jun 2024
Anthem (NYSE:ANTM)
Historical Stock Chart
From Jun 2023 to Jun 2024